Litigation Details for SHIRE PHARMACEUTICAL DEVELOPMENT INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

SHIRE PHARMACEUTICAL DEVELOPMENT INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

Docket		Date Filed	2015-04-22
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Robert B. Kugler
Jury Demand	None	Referred To
Patents	6,773,720
Link to Docket	External link to docket

Details for SHIRE PHARMACEUTICAL DEVELOPMENT INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-08-02	117		certain terms contained with U.S. Patent 6,773,720 (the “ ’720 Patent”) pursuant to Markman v. Westview…intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history…construction for a given patent are binding on later district courts analyzing the same patent. See Key Pharms…district courts of the same terms in the same patent or patent family are highly relevant and persuasive…to “simple dispersion” elsewhere in the patent, (’720 Patent, col. 1 l. 53), signifying that dispersion	External link to document
2018-10-11	394		covered by U.S. Patent Number 6,773,720 (“ ‘720 patent”).2   Claim 1 of the ‘720 patent recites a  controlled‐release… On 22 April 2015, plaintiff Shire filed a patent infringement suit against defendants Amneal (“the…party. 2 According to the Orange Book, the ‘720 patent expires 8 Jun 2020.     …applications before the FDA, Shire  filed similar patent infringement cases against these ANDA applicants…this nor any other ANDA case involving the ’720 patent can be categorized as  an unqualified prevail.	External link to document